ライフサイエンスコーパス: MAP kinase kinase

1 rylation by the dual-specificity kinase MEK (MAP kinase kinase).

2 nine, enhancing Raf-1 kinase activity toward MAP kinase kinase.

3 sive necrosis, and a weak phosphorylation of MAP kinase kinase.

4 micromol/L), a specific inhibitor of p42/44 MAP kinase kinase.

5 inhibited by PD098059, an inhibitor of Mek/ MAP kinase kinase.

6 gh a pathway that required activation of the MAP kinase kinase.

7 ation of the upstream ERK regulatory element MAP kinase kinase.

8 s in the TXY motif of the activation loop by MAP kinase kinases.

9 nd one or more MAP kinase kinase kinases and MAP kinase kinases.

10 The transfection of a MAP kinase kinase 1 (MEK1) dominant negative mutant cDNA

11 induced phenotype, we utilized the selective MAP kinase kinase 1 (MEK1) inhibitor, PD 098059.

12 tion, PD098059, a synthetic inhibitor of the MAP kinase kinase 1 (MEK1) was employed.

13 UO126, an inhibitor of MAP kinase kinase 1 (MEK1), suppressed focal adhesion ta

14 MNK1 activation is blocked by inhibitors of MAP kinase kinase 1 (Mkk1) and p38, demonstrating that M

15 transfection of constitutively active mutant MAP kinase kinase 1 (MKK1) enhanced endogenous topoisome

16 Conversely, a dominant-negative MAP kinase kinase 1 mutant decreased adhesiveness and st

17 In addition, a MAP kinase kinase 1 specific inhibitor blocked the expan

18 osphorylation and p90 ribosomal S6 kinase 2, MAP kinase kinase 1, and Raf-1 activities were increased

19 Upon dual phosphorylation by MAP kinase kinase 1, the dynamics of assigned methyls in

20 by transfection with a constitutively active MAP kinase kinase 1.

21 158780 potently inhibited the LPA-stimulated MAP kinase kinase 1/2 (MKK1/2) activation and EGF recept

22 The in vivo administration of the MAP kinase kinase 1/2 inhibitor U0126 [1,4-diamino-2,3-d

23 ted protein kinases 1 and 2 (ERK1, ERK2) and MAP kinase kinases 1 and 2 (MKK1, MKK2), is well-known t

24 ion of mKsr-1 and mitogen-activated protein (MAP) kinase kinase 1 (MAPKK-1 or MEK-1).

25 it, respectively, mitogen-activated protein (MAP) kinase kinase 1 (MEK 1) and calcineurin, to determi

26 We show that both mitogen-activated protein (MAP) kinase kinase 1 (MEK1) and MAP kinase kinase 2 (MEK

27 , an inhibitor of mitogen-activated protein (MAP) kinase kinase 1 and 2 (MEK1/2) that blocks phosphor

28 of C-Raf and the mitogen-activated protein (MAP) kinase kinases 1 and 2 (MEK1/2).

29 We report that cdk5 phosphorylates the MAP kinase kinase-1 (MEK1) in vivo as well as the Ras-ac

30 Pretreatment of cells with the MAP kinase kinase-1 (MEK1) inhibitor PD 98059 blocked IL

31 e and constitutively active mutants of human MAP kinase kinase-1 (MKK1) were analyzed by deuterium ex

32 Since the only known targets of MAP kinase kinase-1 are Erk1 and Erk2, these findings ar

33 Coinjection of constitutively active MAP kinase kinase-1, which opposes XCL100's effects on M

34 ted protein (MAP) kinase kinase 1 (MEK1) and MAP kinase kinase 2 (MEK2) are activated by ionizing rad

35 -Pr1 prostate and A427 lung carcinoma lines, Map Kinase Kinase 3 (MAP2K3) on 17q in the NCI-H774 lung

36 with IFNalpha results in activation of both MAP kinase kinase 3 (MKK3) and MAP kinase kinase 6 (MKK6

37 , and c-Jun NH(2)-terminal kinase-1, but not MAP kinase kinase 3 and p38, augmented ARE activation by

38 Since the LeTx-mediated proteolysis of map kinase kinase 3 occurs even in resistant cells, Kif1

39 We also show that cleavage of map kinase kinase 3, a target of LeTx proteolysis, occur

40 of p38alpha relies solely on the presence of MAP kinase kinase 3, despite the expression in brown fat

41 a specific upstream activator of the kinase, MAP kinase kinase 3, resulted in diminished proinflammat

42 CL316,243 (CL) stimulates phosphorylation of MAP kinase kinase 3/6 and p38 MAPK in a time- and dose-d

43 Both FMLP and PAF activated MAP kinase kinase-3 (MKK3), a known activator of p38 MAP

44 ad [FKHR], HSP27, mitogen-activated protein (MAP) kinase kinase-3 and -6 (MKK3/6), the tumor-suppress

45 rs for the p38 kinases, activated mutants of MAP kinase kinase 3b(E) (MKK3bE) and MAP kinase kinase 6

46 ith SERT and a constitutively active form of MAP kinase kinase 3b(E) [MKK3b(E)] increased 5-HT transp

47 We report here that MAP kinase kinase 4 (MKK4) gene disruption does not affe

48 ube development, we examined the activity of MAP kinase kinase 4 (MKK4), a signaling intermediate bet

49 d the in vitro activation of JNK3 alpha 1 by MAP kinase kinase 4 (MKK4), MAP kinase kinase 7 (MKK7),

50 Coexpression of downstream kinases, MAP kinase kinase 4, MAP kinase kinase 6, and c-Jun NH(2

51 vation of Rac1/Cdc42, mixed lineage kinases, MAP kinase kinases 4 and 7, and JNKs plays a required ro

52 JIPs are reported to bind MAP kinase kinases 4/7 and JNKs.

53 Mitogen-activated protein (MAP) kinase kinase 4 (MKK4) is a component of stress act

54 hosphorylation of mitogen-activated protein (MAP) kinase kinase 4, p38, extracellular receptor kinase

55 ivity by blocking mitogen-activated protein (MAP) kinase kinase 4-induced signaling events.

56 experiments confirm that IL-1beta activates MAP kinase kinase-4 (MKK4)/SEK1, MKK3, and MKK6 in renal

57 l MAPK signaling proteins (MEK-1, MEK-3, and MAP kinase kinase-4) and may indicate activity of anthra

58 dominant negative ERK5 or dominant negative MAP kinase kinase 5 reduced the number of neurons genera

59 strongly stimulated by constitutively active MAP kinase kinase 6 (MKK6), an upstream activator of p38

60 ly in the preferred activation of p38beta by MAP kinase kinase 6 (MKK6), whereas p38 was activated ne

61 ation of both MAP kinase kinase 3 (MKK3) and MAP kinase kinase 6 (MKK6).

62 MAPK by expression of constitutively active MAP kinase kinase 6 (MKK6Glu) greatly enhances nuclear t

63 tion of the p38-dependent upstream activator MAP kinase kinase 6 as a member of this group identifies

64 by the expression of constitutivelyactivated MAP kinase kinase 6 in transgenic mice caused increased

65 rtantly, expression of a constitutive active MAP kinase kinase 6(Glu) resulted in the phosphorylation

66 We found that cells expressing MAP kinase kinase 6(Glu), which is the upstream kinase t

67 of downstream kinases, MAP kinase kinase 4, MAP kinase kinase 6, and c-Jun NH(2)-terminal kinase-1,

68 f both the ICE/Ced-3 family of proteases and MAP kinase kinase 6.

69 ycin and ultraviolet radiation (UV) activate MAP kinase kinase-6 (MKK6) [14,15], p38/RK [16] [17,18]

70 Expression of MAP kinase kinase 6b (EE), a constitutive activator of p

71 ants of MAP kinase kinase 3b(E) (MKK3bE) and MAP kinase kinase 6b(E) (MKK6bE), elicited characteristi

72 The MAP kinase kinase 7 (MKK7) gene of Arabidopsis has previ

73 cell activation, the Jun kinase (JNK) kinase MAP kinase kinase 7 (MKK7) is alternatively spliced to f

74 JNK3 alpha 1 by MAP kinase kinase 4 (MKK4), MAP kinase kinase 7 (MKK7), and the combination of MKK4

75 ignaling by the mixed-lineage kinase (MLK)-->MAP kinase kinase 7 (MKK7)-->JNK pathway.

76 minal kinase (JNK) pathway revealed that the MAP kinase kinase 7 (MKK7)-JNK cascade also mediated IFN

77 kinase (IKK), and reduced phosphorylation of MAP kinase kinase 7 and Jun NH2-terminal kinase (JNK).

78 P is critical for mitogen-activated protein (MAP) kinase kinase 7 (MKK7) phosphorylation and recruitm

79 PD 098059, an inhibitor of MAP kinase kinase activation, blocked the effects of NGF

80 , an inhibitor of mitogen-activated protein (MAP) kinase kinase activation, inhibited IGF-stimulated

81 Mutations in the earlier identified fuz7 MAP kinase kinase also suppress the filamentous phenotyp

82 44 MAP kinase, which was reduced by blocking MAP kinase kinase and PKC.

83 nvolving three key kinases, namely Raf, MEK (MAP kinase kinase) and ERK (MAP kinase).

84 nic signaling proteins Src, Ras, Raf-1, Mek (MAP kinase kinase), and Erk (MAP kinase) in baculovirus-

85 tor, mitogen-activated protein (MAP) kinase, MAP kinase kinase, and 14-3-3 proteins.

86 ration, we used U0126, a potent inhibitor of MAP kinase kinase, and a constitutively active mutant of

87 y, including phospho-p38, nNOS, phospho-ASK1 MAP kinase kinase, and active caspase-3.

88 ies, overexpression of constitutively active MAP kinase kinase, and an in vitro assay with recombinan

89 tivities of the upstream regulators of MAPK, MAP kinase kinase, and Raf-1.

90 , which encodes a mitogen-activated protein (MAP) kinase kinase, and nsy-1, which encodes a MAP kinas

91 P kinase kinase kinase; MKK4 and/or MEK1 for MAP kinase kinase; and JNK1 for MAP kinase.

92 These dual specificity kinases also known as MAP kinase kinases are constituents of the sequential ki

93 Both MAP kinase and MEK (MAP kinase kinase) are phosphorylated and active in unfe

94 However, an inhibitor of MAP kinase kinase blocks this action of RafCAAX but has

95 contrast, expression of mutationally active MAP kinase kinase causes activation of MAP kinase leadin

96 e that includes a previously uncharacterized MAP kinase kinase, CrMAPKK1.

97 more, genes that encode two novel Drosophila MAP kinase kinases, D-MKK3 and D-MKK4, were identified.

98 We have identified a MAP kinase kinase (DdMEK1) that is required for proper a

99 dent phosphorylation of synapsin I, and MEK (MAP kinase kinase)/ERK inhibition selectively decreased

100 Phosphorylation and activation of both the MAP kinase kinase/ERK and PI3K/Akt pathways occur in lat

101 highly sensitive to PD98059, an inhibitor of MAP kinase kinase/ERK kinase 1 (MEK1) that blocks activa

102 is mediated via prolonged activation of the MAP kinase kinase/ERK signal pathway.

103 eatment caused marked down-regulation of the MAP kinase kinase/extracellular regulatory kinase (MEK/E

104 re we show that JNKK2, a novel member of the MAP kinase kinase family, was phosphorylated and activat

105 lar cloning of a new member of the mammalian MAP kinase kinase group (MKK7) that functions as an acti

106 Seven distinct mammalian MAP kinases kinases have been identified.

107 thway inhibition is mediated at the level of MAP kinase kinase in a Ras- and Raf-independent fashion,

108 more, this nuclear ERK2 is phosphorylated by MAP kinase kinase in response to growth factors and also

109 ressed by preventing ERK activation with the MAP kinase kinase inhibitor 2-(2-diamino-3-methoxyphenyl

110 Also, systemic administration of an MAP kinase kinase inhibitor increased breakpoint ratios,

111 treatment of extracts with either a specific MAP kinase kinase inhibitor or a MAP kinase phosphatase

112 ompletely abolished by pretreatment with the MAP kinase kinase inhibitor PD 98059 (30 micromol/L, 60

113 atment with pertussis toxin or the synthetic MAP kinase kinase inhibitor PD098059.

114 and secretion of interleukin-8, whereas the MAP kinase kinase inhibitor PD98059 partially inhibited

115 The MAP kinase kinase inhibitor PD98059, or its vehicle, was

116 We synthesized a previously characterized MAP kinase kinase inhibitor to test the effect that bloc

117 Local application of the MAP kinase kinase inhibitor U0126 (1,4-diamino-2,3-dicya

118 PD 098059, a MAP kinase kinase inhibitor, abolished thrombin-induced

119 Treatment of cells with PD-098059, a MAP kinase kinase inhibitor, or with MAP kinase antisens

120 AP kinase) in CD34(+) cells, and we used the MAP kinase kinase inhibitor, PD 098059, which at 30 micr

121 The MAP kinase kinase inhibitor, PD98059, had no effect on a

122 Treatment of human osteoblasts with a MAP kinase kinase inhibitor, PD98059, impaired both basa

123 and that inhibiting Erk activation with the MAP kinase kinase inhibitor, PD98059, reversibly inhibit

124 Finally, using a specific MAP kinase kinase inhibitor, we found that activation of

125 R co-immunoprecipitated with MAP kinase; (3) MAP kinase-kinase inhibitor PD98059 attenuated Ang II-in

126 reatment with the mitogen-activated protein (MAP) kinase kinase inhibitor PD98059.

127 as blocked by the mitogen-activated protein (MAP) kinase kinase inhibitor, PD98059.

128 ppressed by intrathecal delivery of the MEK (MAP kinase kinase) inhibitor U0126.

129 Unexpectedly, two MEK (MAP kinase kinase) inhibitors (PD 98059 and U 0126) enha

130 PI3-kinase and MEK (MAP kinase kinase) inhibitors had very different effects

131 k6, demonstrating that the function of these MAP kinase kinases is required for full activation of th

132 ligases for the dual-leucine-zipper-bearing MAP kinase kinase kinase (DLK MAPKKK) to regulate the si

133 Cot (also known as Tpl2) is a member of the MAP kinase kinase kinase (MAP3K) family that is known to

134 to target Ste11, an evolutionarily conserved MAP kinase kinase kinase (MAP3K) in yeast.

135 nsy-1 encodes a homolog of the human MAP kinase kinase kinase (MAPKKK) ASK1, an activator of

136 h phenotype yielded mutations in wallenda, a MAP kinase kinase kinase (MAPKKK) homologous to vertebra

137 (VIGS) to study the role of candidate plant MAP kinase kinase kinase (MAPKKK) homologs of human MEKK

138 as a novel protein that interacts with Win1 MAP kinase kinase kinase (MAPKKK) of the stress-activate

139 Recently, we set out to identify the MAP kinase kinase kinase (MAPKKK) responsible for this m

140 tosis signal-regulating kinase 1 (ASK1) is a MAP kinase kinase kinase (MAPKKK) that is required for c

141 c-Mos is a germ cell-specific MAP kinase kinase kinase (MAPKKK) that plays an essentia

142 screen in yeast, we have identified a human MAP kinase kinase kinase (MAPKKK) that shares homology w

143 ptosis-signal regulating kinase 1 (ASK1) and MAP kinase kinase kinase 1 (MEKK1), stimulate c-Jun kina

144 ng the important cellular signaling molecule MAP kinase kinase kinase 2 (MAP3K2), at exactly the same

145 Here, we show that MAP kinase kinase kinase 4 (MEKK4) is strongly expressed

146 MEKK1 encodes a MAP kinase kinase kinase and is a member of a tandemly d

147 e 4 (MKK4), a signaling intermediate between MAP kinase kinase kinase and JNK/p38.

148 o domains in other proteins that mediate Ras-MAP kinase kinase kinase associations; however, this RBL

149 tion and the Ras-dependent activation of the MAP kinase kinase kinase B-Raf are blocked by inhibition

150 t studies suggest that Rap1 can activate the MAP kinase kinase kinase B-Raf that is either endogenous

151 Furthermore, the MAP kinase kinase kinase CARD domain-containing protein

152 /thr kinases are most closely related to the MAP kinase kinase kinase family.

153 We identified a MAP kinase kinase kinase gene (MAPKKKalpha) that is requ

154 , a homologue of Mst11, which corresponds to MAP kinase kinase kinase in Magnaporthe oryzae, and urat

155 was phosphorylated and activated by MEKK1, a MAP kinase kinase kinase in the JNK signaling cascade.

156 kinase family that has been shown to act as MAP kinase kinase kinase kinase (MAP4K).

157 Msn probably functions as a MAP kinase kinase kinase kinase in Drosophila, activatin

158 osomal protein S6 kinase p70(S6K1), plus the MAP kinase kinase kinase kinase MINK, which had not prev

159 ddition, a direct PKA site that inhibits the MAP kinase kinase kinase Map3k5 (ASK1) is upstream of JN

160 slational activation of mRNA encoding Mos, a MAP kinase kinase kinase necessary for the activation of

161 identified it as the Mos protooncoprotein, a MAP kinase kinase kinase present at low levels in mitoti

162 roteasomal degradation of TAK1, the upstream MAP kinase kinase kinase required for JNK activation.

163 l cloning and was found to encode a putative MAP kinase kinase kinase similar to CTR1, a negative reg

164 y shown that the conserved actin-interacting MAP kinase kinase kinase Ssk2p/MEKK4, a member of the hi

165 One of these proteins, Sho1, utilizes the MAP kinase kinase kinase Ste11 to activate Pbs2.

166 e it binds the osmosensor Sho1, the upstream MAP kinase kinase kinase Ste11, and the downstream MAP k

167 us with the yeast MAP kinase kinase STE7 and MAP kinase kinase kinase STE11.

168 The MAP kinase kinase kinase TGFbeta-activated kinase 1 (TAK

169 MEKK4 is a MAP kinase kinase kinase that interacts with GADD45 in v

170 s synaptic terminal growth by regulating the MAP kinase kinase kinase Wallenda.

171 c-MOS, a MAP kinase kinase kinase, is a regulator of oocyte matur

172 optosis signal-regulating kinase 1 (ASK1), a MAP kinase kinase kinase, is required for TNF-mediated J

173 in neuronal signaling by a conserved axonal MAP kinase kinase kinase, known as Wallenda (Wnd) in Dro

174 studied the activation mechanism of a human MAP kinase kinase kinase, MTK1 (also known as MEKK4), wh

175 ed effector of polarity signaling, encodes a MAP kinase kinase kinase-related protein that stimulates

176 P) kinase kinase, and nsy-1, which encodes a MAP kinase kinase kinase.

177 etween ubc2 and ubc4, a pheromone-responsive MAP kinase kinase kinase.

178 ng the JNK pathway via an, as yet, undefined MAP kinase kinase kinase.

179 protein kinase cascade: MEKK1, -2, or -4 for MAP kinase kinase kinase; MKK4 and/or MEK1 for MAP kinas

180 y to other fungal mitogen-activated protein (MAP) kinase kinase kinase (MAPKKK) genes.

181 ys including Raf, mitogen-activated protein (MAP) kinase kinase kinase (MEK), and MAP kinases.

182 ation, as well as mitogen-activated protein (MAP) kinase kinase kinase (MEKK) 1, MAP kinase kinase (M

183 s a member of the mitogen-activated protein (MAP) kinase kinase kinase group that has been implicated

184 to members of the mitogen-activated protein (MAP) kinase kinase kinase subfamily, this protein kinase

185 ation of MEKK2, a mitogen-activated protein (MAP) kinase kinase kinase upstream of ERK5 that is requi

186 Mos, a mitogen-activated protein (MAP) kinase kinase kinase, indirectly activates MAP kina

187 ctivates dual leucine-zipper kinase (DLK), a MAP-kinase kinase kinase that then activates MKK7 and ER

188 hough LRRK2 does not function as a canonical MAP-kinase-kinase-kinase.

189 s recent studies characterizing the specific MAP kinase kinase kinases (MAP 3-kinases) that link MAP

190 ase that belongs to the MEKK/STE11 family of MAP kinase kinase kinases (MAP(3)Ks).

191 na there are approximately 80 genes encoding MAP kinase kinase kinases (MAP3K), 10 genes encoding MAP

192 amino acid (TAO) kinases are Ste20p-related MAP kinase kinase kinases (MAP3Ks) that activate p38 MAP

193 tein kinases: (i) the SSK2, SSK22, and STE11 MAP kinase kinase kinases (MAPKKKs), (ii) the PBS2 MAPKK

194 ase cascade composed of the Ssk2p and Ssk22p MAP kinase kinase kinases (MAPKKKs), the Pbs2p MAPKK, an

195 cs4 response regulator and stress-responsive MAP kinase kinase kinases (MAPKKKs).

196 athway, including the mixed-lineage group of MAP kinase kinase kinases (MLK), the MAP kinase kinase M

197 n requires a chitin receptor and one or more MAP kinase kinase kinases and MAP kinase kinases.

198 , depending on the expression pattern of the MAP kinase kinase kinases of the Raf family: Raf-1 and B

199 Two related MAP kinase kinase kinases, apoptosis-signal regulating k

200 Ras binding to members of the Raf family of MAP kinase kinase kinases, C-Raf and B-Raf.

201 we show that TPL-2 , which is homologous to MAP-kinase-kinase kinases in its catalytic domain, forms

202 verexpression and expression of an activated MAP-kinase-kinase (MAP-KK), cytochrome c induced apoptos

203 se kinase kinases (MAP3K), 10 genes encoding MAP kinase kinases (MAP2K), and 20 genes encoding MAP ki

204 Furthermore, constitutively active MAP kinase kinase (MAPKK) activated ERalpha in Cos1 cell

205 r this behavior requires the assumption that MAP kinase kinase (MAPKK) carries out its dual phosphory

206 iparum, but in vitro attempts at identifying MAP kinase kinase (MAPKK) homologues have failed.

207 ivation, we introduced constitutively active MAP kinase kinase (MAPKK) into immortalized melanocytes.

208 upstream pathways that converge on the Pbs2 MAP kinase kinase (MAPKK), leading to the activation of

209 Finally, inhibition of MAP kinase kinase (MAPKK), which phosphorylates and ther

210 However, the role of MAP kinase kinases (MAPKKs) and their functional organiz

211 on specific tyrosine and threonine sites by MAP kinase kinases (MAPKKs) is thought to be the sole ac

212 In vitro studies previously identified the MAP kinase kinases (MAPKKs) MKK3 and MKK6 as the primary

213 nt of the protein tyrosine kinase c-Src, the MAP kinase kinase MEK 1/2, and the transcription factor

214 protein (MAP) kinase kinase kinase (MEKK) 1, MAP kinase kinase (MEK) 3/6, and p38 MAP kinase activati

215 PD98059 and U0126, inhibitors of MAP kinase kinase (MEK) activity, decreased epidermal gr

216 Inhibition of MAP kinase kinase (MEK) during this sustained alphavbeta

217 JNKK2), a subfamily of the dual specificity MAP kinase kinase (MEK) family, through phosphorylation

218 Rottlerin also inhibited the activation of MAP kinase kinase (MEK) in response to activated Raf, bu

219 ascade (wortmannin and LY29004) but not by a MAP kinase kinase (MEK) inhibitor (PD98059) or a protein

220 ine kinase (PTK) inhibitor genistein, by the MAP kinase kinase (MEK) inhibitor PD98059, and by loadin

221 The MAP kinase kinase (MEK) inhibitor UO126 prevented BrdU u

222 In the presence of the MAP kinase kinase (MEK) inhibitor, PD 098059, phagocytos

223 ction was highlighted by the result that the MAP kinase kinase (MEK) inhibitor, PD 98059, blocked Del

224 Inhibition of ERK activity by (a) the MAP kinase kinase (MEK) inhibitor, PD98059, (b) antisens

225 a1 adrenoceptor antagonist, prazosin, or the MAP kinase kinase (MEK) inhibitor, U0126 (1,4-diamino-2,

226 actors was inhibited by PD098059, a specific MAP kinase kinase (MEK) inhibitor.

227 evious studies have shown that activation of MAP kinase kinase (MEK) is insufficient to induce neuron

228 Ras and MAP kinase kinase (MEK) were necessary and sufficient fo

229 n mouse eggs a constitutively active form of MAP kinase kinase (MEK) whose only known target is p42/p

230 f PKG activation was increased activation by MAP kinase kinase (MEK).

231 dopsis thaliana gene encoding a homologue of MAP kinase kinase (MEK).

232 tivator of transcription (STAT) 3, STAT5, or MAP kinase kinase (MEK).

233 pathways at four levels: mitogen receptors, MAP kinase kinase (MEK)1/2 and ERK1/2, and certain downs

234 Selective MAP kinase kinase (MEK)1/2 inhibitors, PD98059 and U0126

235 The MAP kinase kinase (MEK-1) inhibitor PD98059 inhibited IL

236 c MAP kinase inhibitors, PD98059 (25 microM; MAP kinase kinase (MEK-1) inhibitor) and SB203580 (10 mi

237 ransfection with a dominant negative form of MAP kinase kinase (MEK-1).

238 ly, LacCer stimulated the phosphorylation of MAP kinase kinases (MEK) and Raf within 2.5 min.

239 on 3 (STAT-3) and mitogen-activated protein (MAP) kinase kinase (MEK) activity, reduced expression of

240 e comprising Raf, mitogen-activated protein (MAP) kinase kinase (MEK) and MAP kinase is a Ras effecto

241 S1P requires both mitogen-activated protein (MAP) kinase kinase (MEK) and p38 MAP kinase, and MEK is

242 and Erk2-specific mitogen-activated protein (MAP) kinase kinase (MEK) are essential and probably func

243 n-fs, whereas the mitogen-activated protein (MAP) kinase kinase (MEK) inhibitor PD98059 blocked phosp

244 ut the use of the mitogen-activated protein (MAP) kinase kinase (MEK) inhibitor PD98059, were perform

245 ition of the microtubule-associated protein (MAP) kinase kinase (MEK) or overexpression of dominant-n

246 of activation of mitogen-activated protein (MAP) kinase kinase (MEK), and FPT inhibitor II, a select

247 , an inhibitor of mitogen-activated protein (MAP) kinase kinase (MEK), had no effect on the m1 recept

248 e inhibitors as protein kinase CK2, not p38, MAP-kinase kinase (MEK)1/2, phosphatidylinositol 3'-kina

249 d Cu chelators all reduce the ability of the MAP kinase kinase Mek1 to phosphorylate the MAP kinase E

250 vation was demonstrated by inhibition of the MAP kinase kinase MEK1.

251 activity form of its upstream regulator, the MAP kinase kinase MEK1.

252 ERK2, such as the mitogen-activated protein (MAP) kinase kinase MEK1 and MAP kinase phosphatases.

253 e here have investigated this issue by using MAP kinase kinase (MEK1) inhibitor PD098059 and a domina

254 MAP kinase activity based on the use of the MAP kinase kinase (MEK1) inhibitor PD98059.

255 ctor for a constitutively active form of the MAP kinase kinase (MEK1) led to stimulation of PTTG tran

256 enes encoding two mitogen-activated protein (MAP) kinase kinases, MEK1 and MEK2, two MAP kinases, NTF

257 ssion of a constitutively active form of the MAP kinase kinase, MEK2, was sufficient to induce HIF-1

258 erine residues in the activation loop of the MAP kinase kinase, MEK2.

259 occurs independently of Ras and requires the MAP-kinase kinase Mek5.

260 describe a constitutively active form of the MAP kinase kinase, MEK5(D), which selectively activates

261 gulated sequentially by a series of upstream MAP kinase kinases (MEKs) in a signaling cascade.

262 als emanating from their upstream activators MAP kinase kinases (MEKs).

263 the activity of the growth factor-regulated MAP-kinase kinases (MEKs).

264 Transient expression of MAP kinase kinase (MKK) 6b(E), a constitutive activator

265 We show that activation of a specific MAP kinase kinase (MKK), MKK6b, is necessary and suffici

266 The activity and phosphorylation of MAP kinase kinase (MKK)-4, an upstream regulator of JNK,

267 cked by pretreatment with U0126, a selective MAP kinase kinase (MKK)1/2 inhibitor.

268 dbrain dopaminergic neurons by knocking down MAP kinase kinases (MKK) significantly reduced the selec

269 active mutants of mitogen-activated protein (MAP) kinase kinase (MKK), resulting in cell adhesion and

270 The endogenous Arabidopsis MAP kinase kinase MKK1 is activated in cells treated wit

271 dominant-negative mitogen-activated protein (MAP) kinase-kinase (MKK1) abrogated both insulin- and TZ

272 Further, mutants defective in the upstream MAP kinase kinase MKK3 also display hypersensitivity in

273 because it binds to the Rac target MLK3, the MAP kinase kinase MKK3, and the p38 MAP kinase.

274 ase pathway by a mechanism that requires the MAP kinase kinases MKK3 and MKK6.

275 NK activity by a mechanism that requires the MAP kinase kinases MKK4 and MKK7.

276 The p38 MAP kinase kinase MKK6 is identified as a common activat

277 in these cells appears to be mediated by the MAP kinase kinase MKK7 since high levels of MKK7 and low

278 roup of MAP kinase kinase kinases (MLK), the MAP kinase kinase MKK7, and the MAP kinase JNK.

279 carried out by a family of enzymes known as MAP kinase kinases (MKKs or MEKs).

280 ed Rac1/Cdc42, mixed-lineage kinases (MLKs), MAP kinase kinases (MKKs) 4 and 7, c-Jun N-terminal kina

281 timuli on p38 MAP kinase are mediated by the MAP kinase kinases (MKKs) MKK3, MKK4, and MKK6.

282 JNK/SAPKs are activated by specific MAP kinase kinases (MKKs), one of which, MKK4/SEK1, has

283 ation in its conserved TGY motif by upstream MAP kinase kinases (MKKs).

284 and activating a mitogen-activated protein (MAP) kinase kinase named MEK.

285 orskolin or rolipram treatment, but not MEK (MAP kinase kinase) or PI3-K (phosphatidylinositol 3-kina

286 ibition of the MAP kinase p38 but not of the MAP kinase kinase p42/44, suggesting that NO modulates e

287 r tyrosine kinase/mitogen-activated protein (MAP) kinase kinase pathway.

288 yeast high osmolarity response pathway, the MAP kinase kinase Pbs2 is thought to function as a scaff

289 Moreover, using selective inhibitors for MAP kinase kinase (PD98059) and p38 (SB203580), we show

290 Inhibition of MAP kinase kinase, pertussis toxin-sensitive G proteins,

291 rosine kinases or mitogen-activated protein (MAP) kinase kinase prevented the activation of eNOS by E

292 We show that SEK1/MKK4, a MAP kinase kinase proposed to activate SAPK/JNK, is a ve

293 ith the p38 MAPK isoforms themselves and the MAP kinase kinase(s) that regulates them.

294 In contrast, the MAP kinase kinase-specific inhibitor PD98059 had no effe

295 M. grisea that are homologous with the yeast MAP kinase kinase STE7 and MAP kinase kinase kinase STE1

296 olic domain of the signaling mucin Msb2, the MAP kinase kinase Ste7, and the MAP kinase Kss1.

297 nthrax lethal factor), which cleaves certain MAP kinase kinases, strongly reduces both the rate and e

298 LPS-activated PKC zeta phosphorylated MAP kinase kinase, the kinase directly upstream of the E

299 1 in this fraction was able to phosphorylate MAP kinase kinase, whereas cytoplasmic Raf-1 in the same

300 Inhibitors of MEK (MAP kinase kinase), which is responsible for phosphoryla